Malaysian Biotechnology Information Centre

bic.org.my

The Malaysian Biotechnology Information Centre (MABIC) is the first and only NGO that promotes biotechnology in Malaysia and enjoys excellent working relationship with ministries, government agencies, research institutes, universities, trade organizations, embassies and high commissions, media, industry and farmer organizations. MABIC’s mission is to provide scientifically accurate and fact-based resources to all stakeholders and support the government’s efforts in developing the biotechnology sector.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Cell and Gene Therapy, Medical

BIOCENTRIQ AND PANCELLA EXECUTE RESEARCH AGREEMENT TO STUDY STEM CELL-DERIVED NATURAL KILLER CELL EXPANSION TECHNOLOGY

PRNewswire | May 03, 2023

news image

BioCentriq, Inc. and panCELLa, a Pluristyx Company, announced that they have signed a research agreement designed to evaluate the ability of panCELLa's genetically-engineered, induced Pluripotent Stem Cell derived, feeder cells to activate and positively impact the expansion rate, total yield and potency of manufactured NK cells. BioCentriq, a contract development and manufacturing organization focused exclusively on accelerating the development and manufacturing of ce...

Read More

Cell and Gene Therapy, Industrial Impact

ALDEVRON LAUNCHES TYPE-V CRISPR NUCLEASE, EURECA-V™ MAD7®

Aldevron | January 20, 2023

news image

Aldevron®, a worldwide leader in the custom development and production of plasmid DNA, RNA, and proteins for the biotech sector, recently announced the launch of Eureca-V™ nuclease. Eureca-V™, licensed from Inscripta®, is the wild-type MAD7® CRISPR Type-V nuclease at research grade, with GMP to follow. The launch of Aldevron's Eureca-V nuclease at advanced therapies week expands the toolkit of accessible CRISPR nucleases for therapeutic, di...

Read More

ANOTHER TAKEDA/SHIRE R&D EXEC JUMPS SHIP AS PHARVARIS NABS PENG LU AS ITS NEW CMO

FierceBiotech | February 07, 2020

news image

After getting off a $66 million series B round in September last year, hereditary angioedema (HAE) specialist Pharvaris has taken on a seasoned HAE developer to help lead its pipeline. The startup has nabbed former Takeda/Shire exec Peng Lu, M.D., Ph.D., as its chief medical officer; Lu comes from Shire after it has been subsumed into Japanese Big Pharma Takeda and follows a whole host of other execs who have hit the exit amid the merger. At Shire, she led the team that finished up the phase 3 p...

Read More

Industrial Impact

SEROTINY AND TESSERA THERAPEUTICS ENTER INTO COLLABORATION TO ENGINEER AND OPTIMIZE PROGRAMMABLE GENE WRITER PROTEINS

Serotiny | March 01, 2022

news image

Serotiny, a leader in high-throughput therapeutic Multi-Domain Protein engineering, and Tessera Therapeutics, a biotechnology company pioneering a new approach in genetic medicines known as Gene Writing technology, today announced a collaboration to engineer programmable Gene Writer proteins. This collaboration will build on Tessera’s innovations in genome engineering technologies and apply Serotiny’s tMDP mining and design expertise to further optimize Tessera’s programmable G...

Read More
news image

Cell and Gene Therapy, Medical

BIOCENTRIQ AND PANCELLA EXECUTE RESEARCH AGREEMENT TO STUDY STEM CELL-DERIVED NATURAL KILLER CELL EXPANSION TECHNOLOGY

PRNewswire | May 03, 2023

BioCentriq, Inc. and panCELLa, a Pluristyx Company, announced that they have signed a research agreement designed to evaluate the ability of panCELLa's genetically-engineered, induced Pluripotent Stem Cell derived, feeder cells to activate and positively impact the expansion rate, total yield and potency of manufactured NK cells. BioCentriq, a contract development and manufacturing organization focused exclusively on accelerating the development and manufacturing of ce...

Read More
news image

Cell and Gene Therapy, Industrial Impact

ALDEVRON LAUNCHES TYPE-V CRISPR NUCLEASE, EURECA-V™ MAD7®

Aldevron | January 20, 2023

Aldevron®, a worldwide leader in the custom development and production of plasmid DNA, RNA, and proteins for the biotech sector, recently announced the launch of Eureca-V™ nuclease. Eureca-V™, licensed from Inscripta®, is the wild-type MAD7® CRISPR Type-V nuclease at research grade, with GMP to follow. The launch of Aldevron's Eureca-V nuclease at advanced therapies week expands the toolkit of accessible CRISPR nucleases for therapeutic, di...

Read More
news image

ANOTHER TAKEDA/SHIRE R&D EXEC JUMPS SHIP AS PHARVARIS NABS PENG LU AS ITS NEW CMO

FierceBiotech | February 07, 2020

After getting off a $66 million series B round in September last year, hereditary angioedema (HAE) specialist Pharvaris has taken on a seasoned HAE developer to help lead its pipeline. The startup has nabbed former Takeda/Shire exec Peng Lu, M.D., Ph.D., as its chief medical officer; Lu comes from Shire after it has been subsumed into Japanese Big Pharma Takeda and follows a whole host of other execs who have hit the exit amid the merger. At Shire, she led the team that finished up the phase 3 p...

Read More
news image

Industrial Impact

SEROTINY AND TESSERA THERAPEUTICS ENTER INTO COLLABORATION TO ENGINEER AND OPTIMIZE PROGRAMMABLE GENE WRITER PROTEINS

Serotiny | March 01, 2022

Serotiny, a leader in high-throughput therapeutic Multi-Domain Protein engineering, and Tessera Therapeutics, a biotechnology company pioneering a new approach in genetic medicines known as Gene Writing technology, today announced a collaboration to engineer programmable Gene Writer proteins. This collaboration will build on Tessera’s innovations in genome engineering technologies and apply Serotiny’s tMDP mining and design expertise to further optimize Tessera’s programmable G...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us